ArticleDiscover oncology2026
Integrated bioinformatics and in vitro validation reveal the role of CCT5 in immune infiltration and the Wnt pathway in colon cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesWhile Chaperonin Containing TCP1 Subunit 5 (CCT5) is recognized for its involvement in the oncogenesis and advancement of diverse malignancies, its functional significance within the context of colon adenocarcinoma (COAD) has yet to be elucidated.
methodsThis study employed an integrated approach combining multi-omics bioinformatic mining with experimental validation. CCT5 expression patterns, genomic alterations, and their clinical relevance were evaluated using the TCGA, TIMER, and cBioPortal databases. The tumor immune microenvironment was characterized via the CIBERSORT algorithm. To validate these findings, immunohistochemistry (IHC) was performed on a clinical cohort of 107 COAD specimens. Functionally, shRNA-mediated stable knockdown was established in HCT116 and HT29 cell lines. The impact of CCT5 on malignant phenotypes was assessed through CCK-8, EdU, colony formation, and Transwell assays. Finally, the underlying molecular mechanisms were elucidated using Gene Set Variation Analysis (GSVA) and Western blotting to detect key components of the Wnt/β-catenin/Myc signaling axis.
resultsCCT5 was significantly overexpressed in COAD at both the mRNA and protein levels, with high expression serving as an independent risk factor for poor overall survival and advanced clinicopathological stages (T, N, and AJCC stages). Exploratory genomic analysis indicated that CCT5 mutations were associated with poor prognosis. Immune profiling revealed a positive correlation between CCT5 levels and the infiltration of activated CD4 + memory T cells and M1 macrophages. In vitro assays demonstrated that CCT5 depletion markedly attenuated the proliferative, clonogenic, and metastatic potential of COAD cells. Mechanistically, our findings suggest that CCT5 may contribute to tumor progression by activating the Wnt/β-catenin/Myc cascade; its knockdown led to a significant downregulation of Wnt3a, nuclear β-catenin, c-Myc, and Cyclin D1.
conclusionsOur findings identify CCT5 as a critical oncogenic driver in colon adenocarcinoma that facilitates tumor growth and metastasis by modulating the Wnt/β-catenin/Myc signaling pathway. These results highlight CCT5 may serve as a potential prognostic biomarker and a promising therapeutic target for precision oncology in COAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.